Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNO in Unresectable Solid Cutaneous/Subcutaneous Primary or Metastatic Tumors
NCT05351502Phase 1Terminated
- Sponsor
- Beyond Air
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label trial of nitric oxide in solid tumor (3 arms), sponsored by Beyond Air. Primary endpoints: Overall Response Rate at 3 months and Incidence of Adverse Events, Serious Adverse Events, and Dose-Limiting Toxicities at 12 weeks. Started Aug 2022; status: terminated.
02
Drugs
nitric oxide
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05351502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351502.